Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 01 symbols : Amgn save search
Spectrum Pharmaceuticals Announces Changes to Management Team and Board of Directors
Published: 2021-12-01 (Crawled : 22:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: 0.0%
SPPI | $1.03 -0.97% 0
|
Health Technology
|
| O: 1.59%
H: 13.12%
C: 5.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.78%
H: 2.59%
C: 0.18%
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
Published: 2021-12-01 (Crawled : 22:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.7%
H: 3.74%
C: -0.91%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.78%
H: 2.59%
C: 0.18%
psoriasis positive results phase 3 topline
U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Published: 2021-12-01 (Crawled : 21:00) - biospace.com/
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.54%
H: 3.8%
C: 2.35%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.03%
H: 2.04%
C: 0.76%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.55%
H: 0.59%
C: -1.88%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.78%
H: 2.59%
C: 0.18%
fda
FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse
Published: 2021-12-01 (Crawled : 19:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.03%
H: 1.18%
C: 0.22%
fda
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.